Kura May Have Found A Place For Tipifarnib In Head-And-Neck Cancer
The repurposed drug showed substantial improvement over existing therapies in second-line treatment of patients with HRAS-mutant tumors.
You may also be interested in...
Finance Watch: AbCellera, 4DMT, Nanobiotix IPOs Bring In $775m Combined
Public Company Edition: Lilly’s COVID-19 antibody partner AbCellera launched one of the biggest IPOs of 2020, bringing in $483m. Also, two more SPACs went public; Sinovac, Biocryst and Kura Oncology arranged large financings; and Viatris plans post-merger layoffs.
Kura Oncology's Troy Wilson On Precision Medicine For Cancer
Since using a reverse-merger last year to go public, Kura Oncology has resurrected an abandoned Janssen cancer candidate and raised $46.5m in an IPO. CEO Troy Wilson spoke with Scrip about the firm's efforts toward precision medicine in cancer.
Kura launches with $60m to revive Janssen's tipifarnib
Kura Oncology raised $60m in a private placement and plans to complete a reverse merger into a public company to support Phase II clinical trials for tipifarnib, a drug for which Johnson & Johnson's Janssen subsidiary suspended development in multiple cancer indications in 2008.